{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:23:28Z","timestamp":1790807008391,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17987-y","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T08:14:08Z","timestamp":1756714448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive analysis of MAGE-A10 in pan-cancer and its validation in gastric cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Yichen","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baozhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"17987_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348. https:\/\/doi.org\/10.3322\/caac.21763 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"17987_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/cm9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao, W., Chen, H. D., Yu, Y. W., Li, N. & Chen, W. Q. Changing profiles of cancer burden worldwide and in china: a secondary analysis of the global cancer statistics 2020. Chin. Med. J. 134, 783\u2013791. https:\/\/doi.org\/10.1097\/cm9.0000000000001474 (2021).","journal-title":"Chin. Med. J."},{"key":"17987_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/cm9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia, C. et al. Cancer statistics in China and united states, 2022: profiles, trends, and determinants. Chin. Med. J. 135, 584\u2013590. https:\/\/doi.org\/10.1097\/cm9.0000000000002108 (2022).","journal-title":"Chin. Med. J."},{"key":"17987_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl, L., Weng, C. H., Eghbali, S., Wolchok, J. D. & Merghoub, T. Enhancing immunotherapy in cancer by targeting emerging Immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19, 37\u201350. https:\/\/doi.org\/10.1038\/s41571-021-00552-7 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"17987_CR5","doi-asserted-by":"publisher","unstructured":"Zhu, S. et al. Combination strategies to maximize the benefits of cancer immunotherapy. J. Hematol. Oncol. 14 https:\/\/doi.org\/10.1186\/s13045-021-01164-5 (2021).","DOI":"10.1186\/s13045-021-01164-5"},{"key":"17987_CR6","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui, R., Zhou, L. & He, S. Cancer immunotherapies: advances and bottlenecks. Front. Immunol. 14, 1212476. https:\/\/doi.org\/10.3389\/fimmu.2023.1212476 (2023).","journal-title":"Front. Immunol."},{"key":"17987_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","volume":"41","author":"L Lybaert","year":"2023","unstructured":"Lybaert, L. et al. Challenges in neoantigen-directed therapeutics. Cancer Cell. 41, 15\u201340. https:\/\/doi.org\/10.1016\/j.ccell.2022.10.013 (2023).","journal-title":"Cancer Cell."},{"key":"17987_CR8","doi-asserted-by":"publisher","unstructured":"Khemlina, G., Ikeda, S. & Kurzrock, R. The biology of hepatocellular carcinoma: implications for genomic and immune therapies. Mol. Cancer. 16 https:\/\/doi.org\/10.1186\/s12943-017-0712-x (2017).","DOI":"10.1186\/s12943-017-0712-x"},{"key":"17987_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin, P., Toor, S. M., Nair, S., Elkord, E. & V. & Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp. Mol. Med. 50, 1\u201311. https:\/\/doi.org\/10.1038\/s12276-018-0191-1 (2018).","journal-title":"Exp. Mol. Med."},{"key":"17987_CR10","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1840703","volume":"254","author":"P van der Bruggen","year":"1991","unstructured":"van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Sci. (New York N Y). 254, 1643\u20131647. https:\/\/doi.org\/10.1126\/science.1840703 (1991).","journal-title":"Sci. (New York N Y)"},{"key":"17987_CR11","first-page":"5544","volume":"61","author":"P Chomez","year":"2001","unstructured":"Chomez, P. et al. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61, 5544\u20135551 (2001).","journal-title":"Cancer Res."},{"key":"17987_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrc1669","volume":"5","author":"AJ Simpson","year":"2005","unstructured":"Simpson, A. J., Caballero, O. L., Jungbluth, A., Chen, Y. T. & Old, L. J. Cancer\/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer. 5, 615\u2013625. https:\/\/doi.org\/10.1038\/nrc1669 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"17987_CR13","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.2147\/ott.S159491","volume":"11","author":"S Jin","year":"2018","unstructured":"Jin, S. et al. Cancer\/testis antigens (CTAs) expression in resected lung cancer. Onco.Targets Therapy. 11, 4491\u20134499. https:\/\/doi.org\/10.2147\/ott.S159491 (2018).","journal-title":"OncoTargets Therapy"},{"key":"17987_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2012.05.011","volume":"324","author":"DW Meek","year":"2012","unstructured":"Meek, D. W. & Marcar, L. MAGE-A antigens as targets in tumour therapy. Cancer Lett. 324, 126\u2013132. https:\/\/doi.org\/10.1016\/j.canlet.2012.05.011 (2012).","journal-title":"Cancer Lett."},{"key":"17987_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/ijc.25777","volume":"129","author":"E Schultz-Thater","year":"2011","unstructured":"Schultz-Thater, E. et al. MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies. Int. J. Cancer. 129, 1137\u20131148. https:\/\/doi.org\/10.1002\/ijc.25777 (2011).","journal-title":"Int. J. Cancer"},{"key":"17987_CR16","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1002\/ijc.27914","volume":"132","author":"C Mengus","year":"2013","unstructured":"Mengus, C. et al. MAGE-A10 cancer\/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas. Int. J. Cancer. 132, 2459\u20132463. https:\/\/doi.org\/10.1002\/ijc.27914 (2013).","journal-title":"Int. J. Cancer"},{"key":"17987_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/sj.bjc.6604476","volume":"99","author":"S Suzuki","year":"2008","unstructured":"Suzuki, S. et al. MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer. Br. J. Cancer. 99, 350\u2013356. https:\/\/doi.org\/10.1038\/sj.bjc.6604476 (2008).","journal-title":"Br. J. Cancer"},{"key":"17987_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10120-020-01123-y","volume":"24","author":"K Fujiya","year":"2021","unstructured":"Fujiya, K. et al. MAGEA10 expression is a predictive marker of early hepatic recurrence after curative gastrectomy for gastric and gastroesophageal junction cancer. Gastric Cancer: Official J. Int. Gastric Cancer Association Japanese Gastric Cancer Association. 24, 341\u2013351. https:\/\/doi.org\/10.1007\/s10120-020-01123-y (2021).","journal-title":"Gastric Cancer: Official J. Int. Gastric Cancer Association Japanese Gastric Cancer Association"},{"key":"17987_CR19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1186\/s12967-023-04519-3","volume":"21","author":"H Qin","year":"2023","unstructured":"Qin, H. et al. Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk. J. Translational Med. 21, 702. https:\/\/doi.org\/10.1186\/s12967-023-04519-3 (2023).","journal-title":"J. Translational Med."},{"key":"17987_CR20","doi-asserted-by":"publisher","unstructured":"Lisica \u0160iki\u0107, N. et al. MAGE-A10 protein expression in advanced high grade serous ovarian cancer is associated with resistance to First-Line Platinum-Based chemotherapy. Cancers 15 https:\/\/doi.org\/10.3390\/cancers15194697 (2023).","DOI":"10.3390\/cancers15194697"},{"key":"17987_CR21","doi-asserted-by":"publisher","unstructured":"Uhlen, M. et al. A pathology atlas of the human cancer transcriptome. Sci. (New York N Y). 357 https:\/\/doi.org\/10.1126\/science.aan2507 (2017).","DOI":"10.1126\/science.aan2507"},{"key":"17987_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"D Chandrashekar","year":"2017","unstructured":"Chandrashekar, D. et al. (ed, S.) UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia (New York N Y) 19 649\u2013658 https:\/\/doi.org\/10.1016\/j.neo.2017.05.002 (2017).","journal-title":"Neoplasia (New York N Y)"},{"key":"17987_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/epi-2017-0118","volume":"10","author":"V Modhukur","year":"2018","unstructured":"Modhukur, V. et al. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics 10, 277\u2013288. https:\/\/doi.org\/10.2217\/epi-2017-0118 (2018).","journal-title":"Epigenomics"},{"key":"17987_CR24","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556\u2013w560. https:\/\/doi.org\/10.1093\/nar\/gkz430 (2019).","journal-title":"Nucleic Acids Res."},{"key":"17987_CR25","doi-asserted-by":"publisher","first-page":"W214","DOI":"10.1093\/nar\/gkq537","volume":"38","author":"D Warde-Farley","year":"2010","unstructured":"Warde-Farley, D. et al. The genemania prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 38, W214\u2013220. https:\/\/doi.org\/10.1093\/nar\/gkq537 (2010).","journal-title":"Nucleic Acids Res."},{"key":"17987_CR26","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward Understanding the origin and evolution of cellular organisms. Protein Science: Publication Protein Soc. 28, 1947\u20131951. https:\/\/doi.org\/10.1002\/pro.3715 (2019).","journal-title":"Protein Science: Publication Protein Soc."},{"key":"17987_CR27","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013d677. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2025).","journal-title":"Nucleic Acids Res."},{"key":"17987_CR28","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509\u2013w514. https:\/\/doi.org\/10.1093\/nar\/gkaa407 (2020).","journal-title":"Nucleic Acids Res."},{"key":"17987_CR29","doi-asserted-by":"publisher","unstructured":"Fu, J. et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 12 https:\/\/doi.org\/10.1186\/s13073-020-0721-z (2020).","DOI":"10.1186\/s13073-020-0721-z"},{"key":"17987_CR30","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558. https:\/\/doi.org\/10.1038\/s41591-018-0136-1 (2018).","journal-title":"Nat. Med."},{"key":"17987_CR31","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1002\/ijc.32369","volume":"145","author":"JT Fekete","year":"2019","unstructured":"Fekete, J. T. & Gy\u0151rffy, B. ROCplot.org: validating predictive biomarkers of chemotherapy\/hormonal therapy\/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients. Int. J. Cancer. 145, 3140\u20133151. https:\/\/doi.org\/10.1002\/ijc.32369 (2019).","journal-title":"Int. J. Cancer"},{"key":"17987_CR32","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/0008-5472.Can-12-1370","volume":"72","author":"WC Reinhold","year":"2012","unstructured":"Reinhold, W. C. et al. CellMiner: a web-based suite of genomic and Pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 72, 3499\u20133511. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-1370 (2012).","journal-title":"Cancer Res."},{"key":"17987_CR33","doi-asserted-by":"publisher","unstructured":"Xiao, Y. & Yu, D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol. Ther. 221 https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107753 (2021).","DOI":"10.1016\/j.pharmthera.2020.107753"},{"key":"17987_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/0008-5472.Can-18-0014","volume":"79","author":"J Lan","year":"2019","unstructured":"Lan, J. et al. M2 Macrophage-Derived exosomes promote cell migration and invasion in colon cancer. Cancer Res. 79, 146\u2013158. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-0014 (2019).","journal-title":"Cancer Res."},{"key":"17987_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.canlet.2021.02.003","volume":"504","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. OTUD5-mediated deubiquitination of YAP in macrophage promotes M2 phenotype polarization and favors triple-negative breast cancer progression. Cancer Lett. 504, 104\u2013115. https:\/\/doi.org\/10.1016\/j.canlet.2021.02.003 (2021).","journal-title":"Cancer Lett."},{"key":"17987_CR36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399\u2013416. https:\/\/doi.org\/10.1038\/nrclinonc.2016.217 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"17987_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki, N., Jain, A. & Campana, D. NK cells for cancer immunotherapy. Nat. Rev. Drug Discov. 19, 200\u2013218. https:\/\/doi.org\/10.1038\/s41573-019-0052-1 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"17987_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bioactmat.2023.08.001","volume":"31","author":"H Zhang","year":"2024","unstructured":"Zhang, H., Yang, L., Wang, T. & Li, Z. NK cell-based tumor immunotherapy. Bioactive Mater. 31, 63\u201386. https:\/\/doi.org\/10.1016\/j.bioactmat.2023.08.001 (2024).","journal-title":"Bioactive Mater."},{"key":"17987_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao, X. et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol. Cancer. 20, 131. https:\/\/doi.org\/10.1186\/s12943-021-01428-1 (2021).","journal-title":"Mol. Cancer"},{"key":"17987_CR40","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint Blockade. Cell 184, 5309\u20135337. https:\/\/doi.org\/10.1016\/j.cell.2021.09.020 (2021).","journal-title":"Cell"},{"key":"17987_CR41","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood, B., Najafi, M. & Mortezaee, K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review. J. Cell. Physiol. 234, 8509\u20138521. https:\/\/doi.org\/10.1002\/jcp.27782 (2019).","journal-title":"J. Cell. Physiol."},{"key":"17987_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s10020-022-00475-8","volume":"28","author":"J Song","year":"2022","unstructured":"Song, J. et al. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction. Mol. Med. (Cambridge Mass). 28, 47. https:\/\/doi.org\/10.1186\/s10020-022-00475-8 (2022).","journal-title":"Mol. Med. (Cambridge Mass)"},{"key":"17987_CR43","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1373\/clinchem.2019.303644","volume":"65","author":"MJ Duffy","year":"2019","unstructured":"Duffy, M. J. & Crown, J. Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin. Chem. 65, 1228\u20131238. https:\/\/doi.org\/10.1373\/clinchem.2019.303644 (2019).","journal-title":"Clin. Chem."},{"key":"17987_CR44","doi-asserted-by":"publisher","unstructured":"Simister, P. C., Border, E. C., Vieira, J. F. & Pumphrey, N. J. Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy. J. Immunother. Cancer. 10 https:\/\/doi.org\/10.1136\/jitc-2022-004600 (2022).","DOI":"10.1136\/jitc-2022-004600"},{"key":"17987_CR45","doi-asserted-by":"publisher","unstructured":"Blumenschein, G. R. et al. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10\u2009+\u2009advanced non-small cell lung cancer. J. Immunother. Cancer. 10 https:\/\/doi.org\/10.1136\/jitc-2021-003581 (2022).","DOI":"10.1136\/jitc-2021-003581"},{"key":"17987_CR46","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.annonc.2022.09.156","volume":"33","author":"A Acha-Sagredo","year":"2022","unstructured":"Acha-Sagredo, A., Ganguli, P. & Ciccarelli, F. D. Somatic variation in normal tissues: friend or foe of cancer early detection? Ann. Oncol. 33, 1239\u20131249. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.156 (2022).","journal-title":"Ann. Oncol."},{"key":"17987_CR47","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","volume":"37","author":"A Nishiyama","year":"2021","unstructured":"Nishiyama, A. & Nakanishi, M. Navigating the DNA methylation landscape of cancer. Trends Genet. 37, 1012\u20131027. https:\/\/doi.org\/10.1016\/j.tig.2021.05.002 (2021).","journal-title":"Trends Genet."},{"key":"17987_CR48","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-pathol-042220-022304","volume":"17","author":"A Papanicolau-Sengos","year":"2022","unstructured":"Papanicolau-Sengos, A. & Aldape, K. D. N. A. Methylation profiling: an emerging paradigm for cancer diagnosis. Annu. Rev. Pathol. 17, 295\u2013321. https:\/\/doi.org\/10.1146\/annurev-pathol-042220-022304 (2022).","journal-title":"Annu. Rev. Pathol."},{"key":"17987_CR49","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nrc1507","volume":"4","author":"JP Issa","year":"2004","unstructured":"Issa, J. P. CpG Island methylator phenotype in cancer. Nat. Rev. Cancer. 4, 988\u2013993. https:\/\/doi.org\/10.1038\/nrc1507 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"17987_CR50","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1126\/science.aar7854","volume":"362","author":"CJ Harris","year":"2018","unstructured":"Harris, C. J. et al. A DNA methylation reader complex that enhances gene transcription. Sci. (New York N Y). 362, 1182\u20131186. https:\/\/doi.org\/10.1126\/science.aar7854 (2018).","journal-title":"Sci. (New York N Y)"},{"key":"17987_CR51","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","volume":"20","author":"SP Kubli","year":"2021","unstructured":"Kubli, S. P., Berger, T., Araujo, D. V., Siu, L. L. & Mak, T. W. Beyond immune checkpoint blockade: emerging immunological strategies. Nat. Rev. Drug Discovery. 20, 899\u2013919. https:\/\/doi.org\/10.1038\/s41573-021-00155-y (2021).","journal-title":"Nat. Rev. Drug Discovery"},{"key":"17987_CR52","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.Cir-21-0515","volume":"10","author":"N Budimir","year":"2022","unstructured":"Budimir, N., Thomas, G. D., Dolina, J. S. & Salek-Ardakani, S. Reversing T-cell exhaustion in cancer: lessons learned from PD-1\/PD-L1 immune checkpoint Blockade. Cancer Immunol. Res. 10, 146\u2013153. https:\/\/doi.org\/10.1158\/2326-6066.Cir-21-0515 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"17987_CR53","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.ygeno.2019.06.021","volume":"112","author":"Y Masoudi-Sobhanzadeh","year":"2020","unstructured":"Masoudi-Sobhanzadeh, Y., Omidi, Y., Amanlou, M. & Masoudi-Nejad, A. Drug databases and their contributions to drug repurposing. Genomics 112, 1087\u20131095. https:\/\/doi.org\/10.1016\/j.ygeno.2019.06.021 (2020).","journal-title":"Genomics"},{"key":"17987_CR54","doi-asserted-by":"publisher","unstructured":"Guan, W. L., He, Y. & Xu, R. H. Gastric cancer treatment: recent progress and future perspectives. J. Hematol. Oncol. 16 https:\/\/doi.org\/10.1186\/s13045-023-01451-3 (2023).","DOI":"10.1186\/s13045-023-01451-3"},{"key":"17987_CR55","doi-asserted-by":"publisher","unstructured":"Badie, A., Gaiddon, C. & Mellitzer, G. Histone deacetylase functions in gastric cancer. Therapeutic Target? Cancers. 14 https:\/\/doi.org\/10.3390\/cancers14215472 (2022).","DOI":"10.3390\/cancers14215472"},{"key":"17987_CR56","doi-asserted-by":"publisher","unstructured":"Harjunp\u00e4\u00e4, H., Asens, L., Guenther, M., Fagerholm, S. C. & C. & Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front. Immunol. 10 https:\/\/doi.org\/10.3389\/fimmu.2019.01078 (2019).","DOI":"10.3389\/fimmu.2019.01078"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17987-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17987-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17987-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:17:49Z","timestamp":1757132269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17987-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17987"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17987-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5084638\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The data of patients are from public database. Ethical approval is not applicable for this article. This article does not contain any studies with human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"32077"}}